Allianz Asset Management GmbH decreased its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 38.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 144,126 shares of the medical research company’s stock after selling 88,836 shares during the period. Allianz Asset Management GmbH owned about 0.07% of Iqvia worth $18,699,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in IQV. Carillon Tower Advisers Inc. boosted its position in Iqvia by 9.2% in the second quarter. Carillon Tower Advisers Inc. now owns 258,241 shares of the medical research company’s stock worth $25,777,000 after purchasing an additional 21,846 shares during the last quarter. Barings LLC boosted its position in Iqvia by 74.1% in the third quarter. Barings LLC now owns 18,962 shares of the medical research company’s stock worth $2,460,000 after purchasing an additional 8,070 shares during the last quarter. Northern Trust Corp boosted its position in Iqvia by 7.0% in the second quarter. Northern Trust Corp now owns 1,877,470 shares of the medical research company’s stock worth $187,408,000 after purchasing an additional 122,260 shares during the last quarter. Redpoint Investment Management Pty Ltd boosted its position in Iqvia by 25.0% in the second quarter. Redpoint Investment Management Pty Ltd now owns 13,657 shares of the medical research company’s stock worth $1,363,000 after purchasing an additional 2,732 shares during the last quarter. Finally, BP PLC boosted its position in Iqvia by 5.0% in the third quarter. BP PLC now owns 21,000 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 1,000 shares during the last quarter. 89.33% of the stock is currently owned by institutional investors.
Shares of NYSE IQV opened at $117.98 on Friday. Iqvia Holdings Inc has a one year low of $91.57 and a one year high of $135.48. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.09 and a current ratio of 1.09. The firm has a market cap of $24.64 billion, a PE ratio of 27.06, a PEG ratio of 1.77 and a beta of 0.81.
Iqvia (NYSE:IQV) last issued its quarterly earnings results on Monday, October 22nd. The medical research company reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.03. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The firm had revenue of $2.59 billion for the quarter, compared to analysts’ expectations of $2.58 billion. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. As a group, research analysts expect that Iqvia Holdings Inc will post 5.13 EPS for the current fiscal year.
In related news, CFO Michael R. Mcdonnell sold 9,500 shares of the business’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $128.35, for a total transaction of $1,219,325.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director John G. Danhakl sold 370,470 shares of the business’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $124.83, for a total value of $46,245,770.10. The disclosure for this sale can be found here. Insiders have sold a total of 7,117,903 shares of company stock worth $881,082,166 in the last ninety days. Insiders own 6.00% of the company’s stock.
Several research firms have weighed in on IQV. Piper Jaffray Companies boosted their price objective on Iqvia to $131.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 23rd. Wells Fargo & Co boosted their price objective on Iqvia from $120.00 to $140.00 and gave the stock an “outperform” rating in a research report on Monday, August 13th. Argus set a $136.00 price objective on Iqvia and gave the stock a “buy” rating in a research report on Thursday, August 23rd. Zacks Investment Research raised Iqvia from a “hold” rating to a “buy” rating and set a $142.00 price objective on the stock in a research report on Tuesday, October 23rd. Finally, Morgan Stanley boosted their price objective on Iqvia from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Monday, December 3rd. Five research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $134.41.
ILLEGAL ACTIVITY WARNING: “Allianz Asset Management GmbH Has $18.70 Million Position in Iqvia Holdings Inc (IQV)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/12/08/allianz-asset-management-gmbh-has-18-70-million-position-in-iqvia-holdings-inc-iqv.html.
Iqvia Company Profile
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Further Reading: What are the benefits of a balanced fund?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.